Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rotavirus Gastroenteritis
Conditions
Rotavirus Gastroenteritis, Diphtheria, Tetanus, Pertussis
Trial Timeline
Dec 1, 2009 → Sep 1, 2010
NCT ID
NCT01003431About Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP) is a phase 3 stage product being developed by Merck for Rotavirus Gastroenteritis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01003431. Target conditions include Rotavirus Gastroenteritis, Diphtheria, Tetanus.
What happened to similar drugs?
1 of 12 similar drugs in Rotavirus Gastroenteritis were approved
Approved (1) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01003431 | Phase 3 | Withdrawn |
Competing Products
14 competing products in Rotavirus Gastroenteritis